Back to Search Start Over

Nonlinear relationships of circulating polyunsaturated fatty acids with the complications of liver cirrhosis: A prospective, longitudinal cohort study.

Authors :
Guo C
Liu Z
Fan H
Wang H
Zhang X
Zhao S
Li Y
Wang T
Dai L
Huang J
Chen X
Zhang T
Source :
Clinical nutrition (Edinburgh, Scotland) [Clin Nutr] 2024 Sep; Vol. 43 (9), pp. 2083-2091. Date of Electronic Publication: 2024 Jul 31.
Publication Year :
2024

Abstract

Background & Aims: The role of circulating polyunsaturated fatty acids (PUFAs) in preventing liver cirrhosis complications remains unclear.<br />Methods: Between 2006 and 2010, 273,834 UK Biobank participants with plasma PUFA quantification data were enrolled and followed up until October 31, 2022. Plasma PUFAs were quantified using a high-throughput nuclear magnetic resonance-based metabolic profiling platform. Liver cirrhosis complications were defined as hospitalization for liver cirrhosis or presentation with hepatocellular carcinoma.<br />Results: During a median follow-up of 13.9 years, 2026 participants developed liver cirrhosis complications. Total plasma PUFAs, omega-3 PUFAs, docosahexaenoic acid (DHA), omega-6 PUFAs, and linoleic acid (LA) were inversely associated with the risk of liver cirrhosis complications, whereas the plasma omega-6/omega-3 ratio was positively associated. Nonparametrically restricted cubic spline regression showed nonlinear associations of plasma PUFAs with liver cirrhosis complications. The inflection points were 4.78 mmol/L for total PUFAs, 0.73 mmol/L for omega-3 PUFAs, 0.25 mmol/L for DHA, 4.07 mmol/L for omega-6 PUFAs, and 2.99 mmol/L for LA. Plasma omega-3 PUFAs were negatively associated with the risk of liver cirrhosis complications when omega-3 PUFAs were <0.73 mmol/L (adjusted hazard ratio [HR], 0.11 [0.08-0.16]), whereas the association was inverted when omega-3 PUFAs were ≥0.73 mmol/L (adjusted HR, 1.87 [1.20-2.92]).<br />Conclusions: The protective effect of plasma omega-3 PUFAs on liver cirrhosis complications is reversed after passing the corresponding inflection point, suggesting an optimal dietary omega-3 PUFA supplementation dose.<br />Competing Interests: Conflict of interest The authors declare that they have no competing interests.<br /> (Copyright © 2024 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.)

Details

Language :
English
ISSN :
1532-1983
Volume :
43
Issue :
9
Database :
MEDLINE
Journal :
Clinical nutrition (Edinburgh, Scotland)
Publication Type :
Academic Journal
Accession number :
39094473
Full Text :
https://doi.org/10.1016/j.clnu.2024.07.027